The Effect of Polymorphism of the GUCY1A3 rs7692387 Gene on Cardiovascular Events After Coronary Artery Bypass Grafting.

Novosibirsk Scientific Research Institute for Circulatory Pathology

Status: Enrolling

Conditions: to Evaluate the Association of GUCY1A3 rs7692387 Gene Polymorphism Carrier on the Development of Cardiovascular Events After Coronary Artery Bypass Grafting

Treatments: Genetic: coronary artery bypass grafting

Study type: Observational

Funder types: Other

Identifiers

NCT06215300

GUCY1A3 rs7692387

Details and patient eligibility

About

Polymorphism in the GUCY1A3 gene worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. Studies have shown the association of the GUCY1A3 gene with the risk of coronary heart disease and its complications, with ischemic stroke

Full description

Acetylsalicylic acid is indicated for the prevention of cardiovascular complications after CABG. Class I. The level of evidence A. ECS recommendations, Russian recommendations of cardiologists. However, the main problem of CABG remains thrombotic and thromboembolic complications in the immediate and long-term postoperative period, despite taking acetylsalicylic acid. According to various sources, the resistance to ASA among the population ranges from 5 to 45%. Resistance to ASA is primarily associated with genetic factors: the presence of polymorphisms of genes encoding platelet receptor proteins, and the functional activity of soluble guanylate cyclase (rCC), the synthesis of which is controlled by the GUCY1A3 gene. Studies have shown a link between the GUCY1A3 gene and the risk of coronary heart disease and its complications. The presence of polymorphism in the GUCY1A3 gene significantly worsens the activity of rCC, causing vasoconstriction and increased platelet aggregation. At the same time, acetylsalicylic acid cannot provide effective prevention of thrombotic and thromboembolic complications.

Enrollment: 800 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Stable ischemic disease 2- 4
• CABG

Exclusion criteria

• the need to take any anticoagulants
• thrombocytopenia
• allergy to aspirin.

Trial design

800 participants in 2 patient groups

genotype GG

Description:

GG

Treatment:

Genetic: coronary artery bypass grafting

genotype AG/АА

Description:

AG/АА

Treatment:

Genetic: coronary artery bypass grafting